TRACON Pharmaceuticals (NASDAQ:TCON) Inc (NASDAQ:TCON) CEO Charles Theuer spoke to Proactive about the latest advancements on its ENVASARC trial to treat cancer with its therapy called envafolimab.
Theuer says that the Independent Data Monitoring Committee has recommended that the trial proceed as planned after reviewing the 12-week safety data from more than 20 patients enrolled in the study as of May 2021. Theuer discussed additional advancements including its recent financing of $15M, its new hires, and its orphan drug designation from the FDA.